Reality check: Can current COVID-19 vaccines fight Omicron? - Kalkine Media

December 21, 2021 04:35 PM AEDT | By Team Kalkine Media
Follow us on Google News:


  • Omicron – which is the latest variant of COVID-19 to have raised concerns, is said to have several mutations.
  • The World Health Organization has labelled it as a 'variant of concern' (VOC).
  • The need of the hour is to find out the efficacy of various vaccines against Omicron.

A new strain of coronavirus SARS-Cov-2, Omicron has become a hot topic of discussion worldwide for its increasing number of cases across different countries.

The United Nations’ specialised agency for international public health, World Health Organization has also designated it as a ‘variant of concern’ considering preliminary research that this virus has more potential of causing infection than others. This virus variant is said to have genetic modifications that are expected or known to affect traits like transmissibility, illness severity, immune escape, diagnostic or therapeutic escape.

Recommended actions by WHO against Omicron

  • Developing a better understanding of the circulating SARS-CoV-2 variants by increasing monitoring and sequencing activities.
  • Complete genome sequences and accompanying metadata should be submitted to a publicly accessible database, such as ‘Global initiative on sharing all influenza data’ (GISAID).
  • Field investigations and laboratory assessments should be conducted to improve understanding of the potential impacts of the VOC.

Also read: Macro-bound week to steer equities as Omicron worries stay

Transmissibility of Omicron and efficacy of vaccines

Efficacy of vaccines against breakthrough of new corona variant

Image source: © Viewimage  |

It's uncertain whether Omicron is more transmissible (that is, easier to spread from person to person) than other variants like Delta. The number of people testing positive has increased in regions across the world. Research studies are being planned to assess if this is attributable to Omicron or other variables.

Scientists are unsure how serious the Omicron variant is or whether it will affect the protection provided by current vaccines. There's further conflicting information about immunisations' ability to protect patients against the Omicron version.

Initial laboratory studies demonstrate that two doses of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) exhibit significantly reduced neutralisation effects, however three doses are required to neutralise the Omicron variant.

Albert Bourla, Chairman and Chief Executive Officer, Pfizer said, “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine.”

In another research, the COVID-19 vaccine created by China's state-owned Sinopharm and Johnson & Johnson, as well as the Russian-designed Sputnik vaccine, were found to elicit little or no antibodies against Omicron.

To know more, read here.

Reality check: Can current COVID-19 vaccines fight Omicron?


Bottom line

Till date, no specific vaccine has proven itself completely effective against Omicron. To analyse and validate protection against Omicron and inform the most effective path ahead, vaccine companies will continue to collect more laboratory data and evaluate real-world effectiveness.

Do read: Can COVID-19 vaccines help protect from Omicron variant?


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK